Please use this identifier to cite or link to this item:
http://repository.kln.ac.lk/handle/123456789/18572
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Siriwardana, R.C. | en_US |
dc.contributor.author | Thilakarathne, S. | en_US |
dc.contributor.author | Niriella, M.A. | en_US |
dc.contributor.author | Dassanayake, A.S. | en_US |
dc.contributor.author | Gunetilleke, M.B. | en_US |
dc.contributor.author | Habarakada, L.C.A. | en_US |
dc.contributor.author | de Silva, H.J. | en_US |
dc.date.accessioned | 2018-01-02T10:35:02Z | en_US |
dc.date.available | 2018-01-02T10:35:02Z | en_US |
dc.date.issued | 2017 | en_US |
dc.identifier.citation | BMC Gastroenterology.2017;17(1):142 | en_US |
dc.identifier.issn | 1471-230X (Electronic) | |
dc.identifier.uri | http://repository.kln.ac.lk/handle/123456789/18572 | |
dc.description.abstract | BACKGROUND: Alpha-fetoprotein (AFP) is a biomarker for hepatocellular carcinoma (HCC). The significance of pre-treatment AFP (pt-AFP) in non-viral HCC (nvHCC) is not clear. METHODS: Patients with nvHCC, referred to a Hepatobiliary Clinic from September 2011-2015 were screened. HCC was diagnosed using American Association for the Study of Liver Disease guidelines, and TNM staged. nvHCC was diagnosed when HBsAg and anti-HCVAb was negative. Child-Turcotte-Pugh (CTP) and Model for End-stage Liver Disease (MELD) scores were calculated. AFP level was evaluated against patient characteristics, tumour characteristics and survival. RESULTS: Three hundred eighty-nine patients with nvHCC [age 64(12-88) years; 344(88.4%) males] were screened. Median AFP was 25.46 ng/ml (1.16-100,000). 41.2% (n = 160) Of patients had normal AFP level. 22.9% (n = 89) had AFP over 400 ng/ml. Female gender (P < 0.05), vascular invasion (P < 0.001), tumours over 5 cm (P < 0.05), late TNM stage (P < 0.001) and non-surgical candidates had higher AFP levels. Diffuse type (P < 0.001), macro vascular invasion (P < 0.001) and late stage tumours (P < 0.001) had AFP over 400 ng/ml. Having AFP below 400 ng/ml was associated with longer survival (16 vs. 7 months, P < 0.001). CONCLUSION: Pre treatment AFP has a limited value In diagnosing nvHCC, Having a AFP value over 400 ng/ml was associated with aggressive tumour behaviour and poor prognosis. | en_US |
dc.language.iso | en_US | en_US |
dc.publisher | BioMed Central | en_US |
dc.subject | Carcinoma, Hepatocellular | en_US |
dc.subject | Carcinoma hepatocellular-aetiology | en_US |
dc.subject | Carcinoma, Hepatocellular-therapy | en_US |
dc.subject | alpha-Fetoproteins | en_US |
dc.subject | Prospective Studies | en_US |
dc.title | Pre-treatment alphafeto protein in hepatocellular carcinoma with non-viral aetiology - a prospective study | en_US |
dc.type | Article | en_US |
Appears in Collections: | Journal/Magazine Articles |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
BMCgas.2017.pdf | 500.82 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.